Corticosteroid and tofacitinib use in patients with inflammatory bowel disease correlated with increased total cholesterol levels, according to research published in Alimentary Pharmacology and Therapeutics.

“Patients with an active chronic inflammatory disease have lower levels of total cholesterol, HDL-cholesterol (HDL-c) and LDL-cholesterol (LDL-c) compared with patients who are in disease remission and the general population. This so-called “lipid paradox” has been mirrored in other inflammatory states,” Jasmijn A.M. Sleutjes, MD, Erasmus Medical Center, and

Full Article: